The latest price target for Xeris Biopharma Holdings (NASDAQ:XERS) was reported by HC Wainwright & Co. on November 11, 2024. The analyst firm set a price target for $6.60 expecting XERS to rise to within 12 months (a possible 126.80% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Xeris Biopharma Holdings (NASDAQ:XERS) was provided by HC Wainwright & Co., and Xeris Biopharma Holdings maintained their buy rating.

There is no last upgrade for Xeris Biopharma Holdings

The last downgrade for Xeris Biopharma Holdings Inc happened on November 11, 2024 when Piper Sandler changed their price target from $3 to $3 for Xeris Biopharma Holdings Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Xeris Biopharma Holdings, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Xeris Biopharma Holdings was filed on November 11, 2024 so you should expect the next rating to be made available sometime around November 11, 2025.

While ratings are subjective and will change, the latest Xeris Biopharma Holdings (XERS) rating was a maintained with a price target of $6.00 to $6.60. The current price Xeris Biopharma Holdings (XERS) is trading at is $2.91, which is out of the analyst’s predicted range.